AAPL347.73-0.50 (-0.14%) ▼|ABBV285.64+0.45 (+0.16%) ▲|ABT103.70+1.19 (+1.16%) ▲|ACN249.37-9.37 (-3.62%) ▼|ADBE263.82-6.73 (-2.49%) ▼|AMAT377.24+1.66 (+0.44%) ▲|AMD516.79+8.86 (+1.74%) ▲|AMGN439.26-8.02 (-1.79%) ▼|AMT188.97+7.40 (+4.08%) ▲|AMZN248.00-2.38 (-0.95%) ▼|AVGO321.68-1.56 (-0.48%) ▼|AXP313.22-11.95 (-3.68%) ▼|BA188.35+0.80 (+0.43%) ▲|BAC50.56-0.52 (-1.02%) ▼|BKNG155.83-5.27 (-3.27%) ▼|BLK1,118.25-19.04 (-1.67%) ▼|BMY61.48-1.52 (-2.41%) ▼|BNY145.27-0.05 (-0.03%) ▼|BRK-B542.19-4.78 (-0.87%) ▼|C120.62-1.89 (-1.54%) ▼|CAT687.00-17.05 (-2.42%) ▼|CL94.04-3.35 (-3.44%) ▼|CMCSA22.69-0.15 (-0.66%) ▼|COF201.34-2.09 (-1.03%) ▼|COP150.80+5.17 (+3.55%) ▲|COST1,003.32-14.89 (-1.46%) ▼|CRM248.57-1.72 (-0.69%) ▼|CSCO106.50+1.61 (+1.53%) ▲|CVS93.47-1.01 (-1.07%) ▼|CVX233.21+6.53 (+2.88%) ▲|DE646.15+2.53 (+0.39%) ▲|DHR230.50+0.75 (+0.33%) ▲|DIS112.52-0.61 (-0.54%) ▼|DUK124.98-0.42 (-0.33%) ▼|EMR161.59+1.30 (+0.81%) ▲|FDX298.72-5.20 (-1.71%) ▼|GD349.36-1.43 (-0.41%) ▼|GE285.64-7.90 (-2.69%) ▼|GEV815.00-12.42 (-1.50%) ▼|GILD156.04-1.15 (-0.73%) ▼|GM75.92-1.29 (-1.67%) ▼|GOOG317.28-3.48 (-1.08%) ▼|GOOGL320.21-4.01 (-1.24%) ▼|GS875.68-15.62 (-1.75%) ▼|HD319.83-7.90 (-2.41%) ▼|HON221.15+2.84 (+1.30%) ▲|IBM253.56+1.45 (+0.58%) ▲|INTC86.96+1.47 (+1.72%) ▲|INTU343.39-11.51 (-3.24%) ▼|ISRG452.29+8.44 (+1.90%) ▲|JNJ263.81-3.80 (-1.42%) ▼|JPM331.58-4.96 (-1.47%) ▼|KO92.71-2.63 (-2.76%) ▼|LIN508.83-1.53 (-0.30%) ▼|LLY1,273.46-33.23 (-2.54%) ▼|LMT604.18+14.27 (+2.42%) ▲|LOW198.68-5.69 (-2.78%) ▼|LRCX230.10-0.05 (-0.02%) ▼|MA623.60-9.61 (-1.52%) ▼|MCD248.46-4.17 (-1.65%) ▼|MDLZ63.80-1.39 (-2.13%) ▼|MDT95.41-1.18 (-1.22%) ▼|META642.62-6.23 (-0.96%) ▼|MMM173.46-2.10 (-1.20%) ▼|MO74.31-1.76 (-2.31%) ▼|MRK145.27-1.97 (-1.34%) ▼|MS179.49-4.48 (-2.44%) ▼|MSFT524.51+3.43 (+0.66%) ▲|MU877.55+21.06 (+2.46%) ▲|NEE82.10+0.20 (+0.24%) ▲|NFLX65.85-1.20 (-1.79%) ▼|NKE37.30-1.02 (-2.66%) ▼|NOW158.96+1.96 (+1.25%) ▲|NVDA210.96-1.25 (-0.59%) ▼|ORCL126.16+0.62 (+0.49%) ▲|PEP135.77-3.06 (-2.20%) ▼|PFE30.03-0.39 (-1.28%) ▼|PG161.02-3.48 (-2.12%) ▼|PLTR196.75+0.56 (+0.29%) ▲|PM199.47-2.27 (-1.13%) ▼|QCOM175.91+3.08 (+1.78%) ▲|RTX191.01-3.70 (-1.90%) ▼|SBUX100.80-1.11 (-1.09%) ▼|SCHW90.58-0.86 (-0.94%) ▼|SO92.89-0.93 (-0.99%) ▼|SPG211.63-0.41 (-0.19%) ▼|T20.93-1.81 (-7.96%) ▼|TMO673.82-2.72 (-0.40%) ▼|TMUS146.54-12.25 (-7.71%) ▼|TSLA372.22-2.36 (-0.63%) ▼|TXN284.69+5.19 (+1.86%) ▲|UBER66.70-2.37 (-3.43%) ▼|UNH418.09-6.89 (-1.62%) ▼|UNP292.87-5.22 (-1.75%) ▼|UPS101.06-0.46 (-0.45%) ▼|USB59.58-0.44 (-0.73%) ▼|V407.92-6.42 (-1.55%) ▼|VZ44.66-0.54 (-1.19%) ▼|WFC82.39-0.62 (-0.75%) ▼|WMT119.89-1.23 (-1.02%) ▼|XOM183.21+4.98 (+2.79%) ▲|AAPL347.73-0.50 (-0.14%) ▼|ABBV285.64+0.45 (+0.16%) ▲|ABT103.70+1.19 (+1.16%) ▲|ACN249.37-9.37 (-3.62%) ▼|ADBE263.82-6.73 (-2.49%) ▼|AMAT377.24+1.66 (+0.44%) ▲|AMD516.79+8.86 (+1.74%) ▲|AMGN439.26-8.02 (-1.79%) ▼|AMT188.97+7.40 (+4.08%) ▲|AMZN248.00-2.38 (-0.95%) ▼|AVGO321.68-1.56 (-0.48%) ▼|AXP313.22-11.95 (-3.68%) ▼|BA188.35+0.80 (+0.43%) ▲|BAC50.56-0.52 (-1.02%) ▼|BKNG155.83-5.27 (-3.27%) ▼|BLK1,118.25-19.04 (-1.67%) ▼|BMY61.48-1.52 (-2.41%) ▼|BNY145.27-0.05 (-0.03%) ▼|BRK-B542.19-4.78 (-0.87%) ▼|C120.62-1.89 (-1.54%) ▼|CAT687.00-17.05 (-2.42%) ▼|CL94.04-3.35 (-3.44%) ▼|CMCSA22.69-0.15 (-0.66%) ▼|COF201.34-2.09 (-1.03%) ▼|COP150.80+5.17 (+3.55%) ▲|COST1,003.32-14.89 (-1.46%) ▼|CRM248.57-1.72 (-0.69%) ▼|CSCO106.50+1.61 (+1.53%) ▲|CVS93.47-1.01 (-1.07%) ▼|CVX233.21+6.53 (+2.88%) ▲|DE646.15+2.53 (+0.39%) ▲|DHR230.50+0.75 (+0.33%) ▲|DIS112.52-0.61 (-0.54%) ▼|DUK124.98-0.42 (-0.33%) ▼|EMR161.59+1.30 (+0.81%) ▲|FDX298.72-5.20 (-1.71%) ▼|GD349.36-1.43 (-0.41%) ▼|GE285.64-7.90 (-2.69%) ▼|GEV815.00-12.42 (-1.50%) ▼|GILD156.04-1.15 (-0.73%) ▼|GM75.92-1.29 (-1.67%) ▼|GOOG317.28-3.48 (-1.08%) ▼|GOOGL320.21-4.01 (-1.24%) ▼|GS875.68-15.62 (-1.75%) ▼|HD319.83-7.90 (-2.41%) ▼|HON221.15+2.84 (+1.30%) ▲|IBM253.56+1.45 (+0.58%) ▲|INTC86.96+1.47 (+1.72%) ▲|INTU343.39-11.51 (-3.24%) ▼|ISRG452.29+8.44 (+1.90%) ▲|JNJ263.81-3.80 (-1.42%) ▼|JPM331.58-4.96 (-1.47%) ▼|KO92.71-2.63 (-2.76%) ▼|LIN508.83-1.53 (-0.30%) ▼|LLY1,273.46-33.23 (-2.54%) ▼|LMT604.18+14.27 (+2.42%) ▲|LOW198.68-5.69 (-2.78%) ▼|LRCX230.10-0.05 (-0.02%) ▼|MA623.60-9.61 (-1.52%) ▼|MCD248.46-4.17 (-1.65%) ▼|MDLZ63.80-1.39 (-2.13%) ▼|MDT95.41-1.18 (-1.22%) ▼|META642.62-6.23 (-0.96%) ▼|MMM173.46-2.10 (-1.20%) ▼|MO74.31-1.76 (-2.31%) ▼|MRK145.27-1.97 (-1.34%) ▼|MS179.49-4.48 (-2.44%) ▼|MSFT524.51+3.43 (+0.66%) ▲|MU877.55+21.06 (+2.46%) ▲|NEE82.10+0.20 (+0.24%) ▲|NFLX65.85-1.20 (-1.79%) ▼|NKE37.30-1.02 (-2.66%) ▼|NOW158.96+1.96 (+1.25%) ▲|NVDA210.96-1.25 (-0.59%) ▼|ORCL126.16+0.62 (+0.49%) ▲|PEP135.77-3.06 (-2.20%) ▼|PFE30.03-0.39 (-1.28%) ▼|PG161.02-3.48 (-2.12%) ▼|PLTR196.75+0.56 (+0.29%) ▲|PM199.47-2.27 (-1.13%) ▼|QCOM175.91+3.08 (+1.78%) ▲|RTX191.01-3.70 (-1.90%) ▼|SBUX100.80-1.11 (-1.09%) ▼|SCHW90.58-0.86 (-0.94%) ▼|SO92.89-0.93 (-0.99%) ▼|SPG211.63-0.41 (-0.19%) ▼|T20.93-1.81 (-7.96%) ▼|TMO673.82-2.72 (-0.40%) ▼|TMUS146.54-12.25 (-7.71%) ▼|TSLA372.22-2.36 (-0.63%) ▼|TXN284.69+5.19 (+1.86%) ▲|UBER66.70-2.37 (-3.43%) ▼|UNH418.09-6.89 (-1.62%) ▼|UNP292.87-5.22 (-1.75%) ▼|UPS101.06-0.46 (-0.45%) ▼|USB59.58-0.44 (-0.73%) ▼|V407.92-6.42 (-1.55%) ▼|VZ44.66-0.54 (-1.19%) ▼|WFC82.39-0.62 (-0.75%) ▼|WMT119.89-1.23 (-1.02%) ▼|XOM183.21+4.98 (+2.79%) ▲|
10.7 C
New York
Monday, October 26, 2026

Tag: DelveInsight Business Research

newsFORsourcecompanycontentinformation1releasesmarket

Vitiligo Market to Register Incremental Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight

The vitiligo market is witnessing steady growth due to rising disease awareness, improved diagnostic capabilities, and advancements in treatment options such as JAK inhibitors...

TYK2 Inhibitors Market to Drive Enormous Growth by 2034 Due to Strong Pipeline and Expanding Indications | DelveInsight

The TYK2 inhibitor market is expected to witness substantial growth in the coming years, driven by the increasing prevalence of autoimmune diseases, robust clinical...

Interstitial Cystitis Market to Grow Rapidly at a CAGR of 4% During the Study Period (2020-2034) | DelveInsight

The interstitial cystitis market is limited by a few approved treatments and high unmet need. However, pipeline innovation and rising awareness are expected to...

Interstitial Cystitis Market to Grow Rapidly at a CAGR of 4% During the Study Period (2020-2034) | DelveInsight

The interstitial cystitis market is limited by a few approved treatments and high unmet need. However, pipeline innovation and rising awareness are expected to...

Treatment Resistant Hypertension Market Set to Transform at a CAGR of 5% with Increasing Diagnosis and Treatment of Resistant Patients along with Approval and...

The treatment-resistant hypertension (TRH) market is expected to grow in the coming years due to the rising prevalence of uncontrolled hypertension and associated cardiovascular...

THR-β Agonist Market on the Rise: Insights and Projections Upto 2034 | DelveInsight

The THR‑β agonist market is witnessing rapid growth, fueled by the increasing global prevalence of metabolic disorders such as MASH and rare genetic conditions...

THR-β Agonist Market on the Rise: Insights and Projections Upto 2034 | DelveInsight

The THR‑β agonist market is witnessing rapid growth, fueled by the increasing global prevalence of metabolic disorders such as MASH and rare genetic conditions...

Osteosarcoma Market on the Rise in the 7MM During the Forecast Period (2025-2034) with Novel Therapeutics and Technological Innovations | DelveInsight

The dynamics of the osteosarcoma market are anticipated to change due to the extensive R&D activities, entry of novel potential therapies such as HALMB-0168...

Osteosarcoma Market on the Rise in the 7MM During the Forecast Period (2025-2034) with Novel Therapeutics and Technological Innovations | DelveInsight

The dynamics of the osteosarcoma market are anticipated to change due to the extensive R&D activities, entry of novel potential therapies such as HALMB-0168...

Triple-Negative Breast Cancer Market Gearing Up for Impressive Growth at a CAGR of 4.7% During the Forecast Period (2025-2034) | DelveInsight

The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved...

Triple-Negative Breast Cancer Market Gearing Up for Impressive Growth at a CAGR of 4.7% During the Forecast Period (2025-2034) | DelveInsight

The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved...

Alpha-synuclein Inhibitors Market to Witness Strong CAGR Through 2034, Driven by Advances in Neurodegenerative Therapies | DelveInsight

No alpha-synuclein inhibitors are approved, underscoring a major need for therapies that slow or halt Parkinson's progression. Developing safe, brain-penetrant drugs that target toxic...

CD40/CD40L Inhibitors Market on Growth Trajectory Driven by Advancements in Autoimmune and Cancer Therapeutics | DelveInsight

The CD40/CD40L inhibitors market is experiencing steady growth driven by increasing research into autoimmune diseases, organ transplantation, and cancer immunotherapy. The rising prevalence of...

CD40/CD40L Inhibitors Market on Growth Trajectory Driven by Advancements in Autoimmune and Cancer Therapeutics | DelveInsight

The CD40/CD40L inhibitors market is experiencing steady growth driven by increasing research into autoimmune diseases, organ transplantation, and cancer immunotherapy. The rising prevalence of...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDelveInsight Business Research

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers